Determining and reporting the doses in the treatment of glioma patients in the epithermal neutron beam at the Finnish BNCT facility (FIR 1)

Tiina Seppälä, Petri Kotiluoto, Sauli Savolainen, Iiro Auterinen, Pekka Hiismäki, Tom Seren, Antti Kosunen, Carita Aschan, Mika Kortesniemi, Matti Toivonen

Research output: Chapter in Book/Report/Conference proceedingChapter or book articleProfessional

Abstract

The clinical trials of glioma patients at the Finnish boron neutron capture therapy (BNCT) facility (FiR 1) started in May 1999. The doses of the patient in tumour, target volume and sensitive tissues are calculated individually. The calculated doses are calibrated to the reference monitor units according to the ratio of the independently measured and calculated 197Au(n,g) reactions rates at the depth of 20 mm on the central axis of a cylindracal PMMA phantom chosen as the reference geometry. Absorbed doses to the head and body are monitored individually using in vivo dosimeters. In BNCT the total dose is the weighted sum of the absorbed doses originating from the neutron and gamma interactions in tissues. The material compositions of the head model for the neutron-gamma transport calculation and kema factors are based on the ICRU report 46. The doses in the clinical research of BNCT should be reported in such a way that the doses are comparable, traceable and can be recalculated, if underlying information, like weighting factors for dose components, are replaced by new ones. The minimum, average and reference doses are reported for the tumour, target and normal brain. In addition to the total weighted doses the dose components (boron, gamma, nitrogen, and fast neutron dose), weighting factors and estimated boron concentration in these tissues are reported. There are no international recommendations available for BNCT dose calculation or reporting. Therefore the BNCT doses reported in the literature may not be comparable and a careless use of values can lead to over- or underdosing. There is an obvious need for standardisation in the medical application of BNCT. In this paper the methods of dose calculation and reporting of the glioma patients at FiR 1 are described.
Original languageEnglish
Title of host publicationCurrent status of neutron capture therapy
Place of PublicationVienna
PublisherInternational Atomic Energy Agency IAEA
ChapterAnnex 9
Pages275-288
Publication statusPublished - 2001
MoE publication typeNot Eligible

Fingerprint

neutron beams
therapy
boron
neutrons
dosage
tumors
standardization
fast neutrons
recommendations
dosimeters
brain
monitors

Cite this

Seppälä, T., Kotiluoto, P., Savolainen, S., Auterinen, I., Hiismäki, P., Seren, T., ... Toivonen, M. (2001). Determining and reporting the doses in the treatment of glioma patients in the epithermal neutron beam at the Finnish BNCT facility (FIR 1). In Current status of neutron capture therapy (pp. 275-288). Vienna: International Atomic Energy Agency IAEA.
Seppälä, Tiina ; Kotiluoto, Petri ; Savolainen, Sauli ; Auterinen, Iiro ; Hiismäki, Pekka ; Seren, Tom ; Kosunen, Antti ; Aschan, Carita ; Kortesniemi, Mika ; Toivonen, Matti. / Determining and reporting the doses in the treatment of glioma patients in the epithermal neutron beam at the Finnish BNCT facility (FIR 1). Current status of neutron capture therapy. Vienna : International Atomic Energy Agency IAEA, 2001. pp. 275-288
@inbook{bc79f891a0204a6ca5bbf07cf5a3eccd,
title = "Determining and reporting the doses in the treatment of glioma patients in the epithermal neutron beam at the Finnish BNCT facility (FIR 1)",
abstract = "The clinical trials of glioma patients at the Finnish boron neutron capture therapy (BNCT) facility (FiR 1) started in May 1999. The doses of the patient in tumour, target volume and sensitive tissues are calculated individually. The calculated doses are calibrated to the reference monitor units according to the ratio of the independently measured and calculated 197Au(n,g) reactions rates at the depth of 20 mm on the central axis of a cylindracal PMMA phantom chosen as the reference geometry. Absorbed doses to the head and body are monitored individually using in vivo dosimeters. In BNCT the total dose is the weighted sum of the absorbed doses originating from the neutron and gamma interactions in tissues. The material compositions of the head model for the neutron-gamma transport calculation and kema factors are based on the ICRU report 46. The doses in the clinical research of BNCT should be reported in such a way that the doses are comparable, traceable and can be recalculated, if underlying information, like weighting factors for dose components, are replaced by new ones. The minimum, average and reference doses are reported for the tumour, target and normal brain. In addition to the total weighted doses the dose components (boron, gamma, nitrogen, and fast neutron dose), weighting factors and estimated boron concentration in these tissues are reported. There are no international recommendations available for BNCT dose calculation or reporting. Therefore the BNCT doses reported in the literature may not be comparable and a careless use of values can lead to over- or underdosing. There is an obvious need for standardisation in the medical application of BNCT. In this paper the methods of dose calculation and reporting of the glioma patients at FiR 1 are described.",
author = "Tiina Sepp{\"a}l{\"a} and Petri Kotiluoto and Sauli Savolainen and Iiro Auterinen and Pekka Hiism{\"a}ki and Tom Seren and Antti Kosunen and Carita Aschan and Mika Kortesniemi and Matti Toivonen",
note = "{"}Papers presented at the Technical Committee Meeting on Current Issues Related to Neutron Capture Therapy, held in Vienna from 14 to 18 June 1999, are given in the annexes.{"}",
year = "2001",
language = "English",
pages = "275--288",
booktitle = "Current status of neutron capture therapy",
publisher = "International Atomic Energy Agency IAEA",
address = "Austria",

}

Seppälä, T, Kotiluoto, P, Savolainen, S, Auterinen, I, Hiismäki, P, Seren, T, Kosunen, A, Aschan, C, Kortesniemi, M & Toivonen, M 2001, Determining and reporting the doses in the treatment of glioma patients in the epithermal neutron beam at the Finnish BNCT facility (FIR 1). in Current status of neutron capture therapy. International Atomic Energy Agency IAEA, Vienna, pp. 275-288.

Determining and reporting the doses in the treatment of glioma patients in the epithermal neutron beam at the Finnish BNCT facility (FIR 1). / Seppälä, Tiina; Kotiluoto, Petri; Savolainen, Sauli; Auterinen, Iiro; Hiismäki, Pekka; Seren, Tom; Kosunen, Antti; Aschan, Carita; Kortesniemi, Mika; Toivonen, Matti.

Current status of neutron capture therapy. Vienna : International Atomic Energy Agency IAEA, 2001. p. 275-288.

Research output: Chapter in Book/Report/Conference proceedingChapter or book articleProfessional

TY - CHAP

T1 - Determining and reporting the doses in the treatment of glioma patients in the epithermal neutron beam at the Finnish BNCT facility (FIR 1)

AU - Seppälä, Tiina

AU - Kotiluoto, Petri

AU - Savolainen, Sauli

AU - Auterinen, Iiro

AU - Hiismäki, Pekka

AU - Seren, Tom

AU - Kosunen, Antti

AU - Aschan, Carita

AU - Kortesniemi, Mika

AU - Toivonen, Matti

N1 - "Papers presented at the Technical Committee Meeting on Current Issues Related to Neutron Capture Therapy, held in Vienna from 14 to 18 June 1999, are given in the annexes."

PY - 2001

Y1 - 2001

N2 - The clinical trials of glioma patients at the Finnish boron neutron capture therapy (BNCT) facility (FiR 1) started in May 1999. The doses of the patient in tumour, target volume and sensitive tissues are calculated individually. The calculated doses are calibrated to the reference monitor units according to the ratio of the independently measured and calculated 197Au(n,g) reactions rates at the depth of 20 mm on the central axis of a cylindracal PMMA phantom chosen as the reference geometry. Absorbed doses to the head and body are monitored individually using in vivo dosimeters. In BNCT the total dose is the weighted sum of the absorbed doses originating from the neutron and gamma interactions in tissues. The material compositions of the head model for the neutron-gamma transport calculation and kema factors are based on the ICRU report 46. The doses in the clinical research of BNCT should be reported in such a way that the doses are comparable, traceable and can be recalculated, if underlying information, like weighting factors for dose components, are replaced by new ones. The minimum, average and reference doses are reported for the tumour, target and normal brain. In addition to the total weighted doses the dose components (boron, gamma, nitrogen, and fast neutron dose), weighting factors and estimated boron concentration in these tissues are reported. There are no international recommendations available for BNCT dose calculation or reporting. Therefore the BNCT doses reported in the literature may not be comparable and a careless use of values can lead to over- or underdosing. There is an obvious need for standardisation in the medical application of BNCT. In this paper the methods of dose calculation and reporting of the glioma patients at FiR 1 are described.

AB - The clinical trials of glioma patients at the Finnish boron neutron capture therapy (BNCT) facility (FiR 1) started in May 1999. The doses of the patient in tumour, target volume and sensitive tissues are calculated individually. The calculated doses are calibrated to the reference monitor units according to the ratio of the independently measured and calculated 197Au(n,g) reactions rates at the depth of 20 mm on the central axis of a cylindracal PMMA phantom chosen as the reference geometry. Absorbed doses to the head and body are monitored individually using in vivo dosimeters. In BNCT the total dose is the weighted sum of the absorbed doses originating from the neutron and gamma interactions in tissues. The material compositions of the head model for the neutron-gamma transport calculation and kema factors are based on the ICRU report 46. The doses in the clinical research of BNCT should be reported in such a way that the doses are comparable, traceable and can be recalculated, if underlying information, like weighting factors for dose components, are replaced by new ones. The minimum, average and reference doses are reported for the tumour, target and normal brain. In addition to the total weighted doses the dose components (boron, gamma, nitrogen, and fast neutron dose), weighting factors and estimated boron concentration in these tissues are reported. There are no international recommendations available for BNCT dose calculation or reporting. Therefore the BNCT doses reported in the literature may not be comparable and a careless use of values can lead to over- or underdosing. There is an obvious need for standardisation in the medical application of BNCT. In this paper the methods of dose calculation and reporting of the glioma patients at FiR 1 are described.

M3 - Chapter or book article

SP - 275

EP - 288

BT - Current status of neutron capture therapy

PB - International Atomic Energy Agency IAEA

CY - Vienna

ER -

Seppälä T, Kotiluoto P, Savolainen S, Auterinen I, Hiismäki P, Seren T et al. Determining and reporting the doses in the treatment of glioma patients in the epithermal neutron beam at the Finnish BNCT facility (FIR 1). In Current status of neutron capture therapy. Vienna: International Atomic Energy Agency IAEA. 2001. p. 275-288